The compounds of the present invention are characterized by a high selectivity towards neoplastic cells. CLL cells show a higher sensitivity towards the compounds than PBMCs opening a therapeutic window. The EC50 for CLL cells is in the lower micromolar range.
Furthermore, compounds have proven activity on different CLL populations.
The activity against CLL cells has been shown in a xenograft model of CLL.
It has been shown that compounds may be suitable for the treatment of other neoplasias.
On behalf of the University of Cologne, we are offering this opportunity for licensing.
A PCT application is pending.
Gehrke I et al.: Ther Adv Hematol. 2011 Oct;2(5):279-89
Razavi R et al.: Clin Cancer Res. 2011 Jan 15;17(2):286-93